Industry Overview

Global prosthetic heart valves market was valued at $10.6 billion in 2025 and is projected to reach $24.2 billion by 2035, growing at a CAGR of 8.6% from 2026 to 2035. The global prosthetic heart valve market is expanding as advancements in medical technology improve patient outcomes and procedural safety. The increasing prevalence of cardiovascular diseases, particularly among aging populations, has heightened the demand for effective valve replacement therapies. Minimally invasive procedures, such as transcatheter valve implantation, are becoming more widely adopted, driving market growth. Rising awareness among healthcare providers and patients about the benefits of timely intervention further supports adoption. Additionally, continuous innovation in valve design and materials enhances durability and performance, encouraging broader clinical acceptance. Expansion of healthcare infrastructure in emerging regions also contributes to the increasing availability and utilization of these devices.

Market Dynamics

Rising Adoption of Minimally Invasive Procedures

The global prosthetic heart valve market is witnessing increased adoption of minimally invasive procedures, particularly transcatheter valve implantation. These approaches reduce recovery time, lower procedural risks, and are preferred for patients who are high-risk surgical candidates. As clinical confidence grows and device approvals expand, more healthcare providers are integrating these procedures into standard practice. Technological improvements in delivery systems and imaging guidance further support their use. This trend is contributing to higher procedure volumes and expanding patient access. Consequently, minimally invasive interventions are becoming a key driver of market growth.

Advancements in Valve Materials and Design

Continuous innovation in valve materials and design is transforming the market by enhancing device durability and performance. New biocompatible and anti-calcification materials extend valve lifespan, reducing the need for repeat procedures. Design improvements, such as flexible frames and optimized flow dynamics, improve hemodynamic outcomes and patient comfort. Manufacturers are investing in research to develop valves suitable for a wider range of patients, including younger and high-risk populations. Regulatory approvals for these advanced devices are increasing their clinical adoption. Overall, these innovations are driving both demand and market expansion globally.

Market Segmentation

• Based on the type, the market is segmented into mechanical heart valves and biological/tissue heart valves.
• Based on the end-users, the market is segmented into hospitals and ambulatory centers.

Mechanical Heart Valves Segment to Lead the Market with the Largest Share

Mechanical heart valves continue to see strong demand due to their long-term durability and suitability for younger patients requiring lifelong valve support. Growth in this segment is supported by increasing awareness among cardiologists and surgeons about the benefits of mechanical valves for high-risk and active patients. Leading manufacturers such as Edwards Lifesciences, Medtronic, and LivaNova are investing in design enhancements to improve hemodynamic performance and reduce complications. Recent trends indicate a focus on minimally invasive implantation techniques for mechanical valves, expanding their clinical adoption. Additionally, the availability of advanced anticoagulation management protocols encourages broader acceptance. The combination of technological innovation and patient preference is sustaining steady growth in this segment.

Hospitals: A Key Segment in Market Growth

Hospitals remain the dominant end-user for prosthetic heart valves, accounting for the majority of procedures globally. Market growth in this segment is fueled by expanding cardiovascular departments, improved surgical infrastructure, and increased procedure volumes. Key players, including Medtronic, Abbott Laboratories, and Boston Scientific, actively partner with hospitals to provide comprehensive training and support for valve implantation. Recent trends highlight the adoption of hybrid operating rooms and advanced imaging systems to facilitate precise valve placement. The rising incidence of heart valve diseases and the preference for hospital-based interventions over outpatient settings further reinforce this segment’s growth. Overall, hospitals continue to drive the adoption and utilization of prosthetic heart valves globally.

Regional Outlook

The global prosthetic heart valves market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region Dominates the Market with Major Share

North America continues to dominate the global prosthetic heart valve market, driven by well-established healthcare infrastructure and high adoption of advanced cardiac procedures. Strong presence of key players such as Edwards Lifesciences, Medtronic, and Abbott Laboratories reinforces market leadership. The region benefits from extensive clinical research, rapid regulatory approvals, and widespread use of minimally invasive technologies like transcatheter valve implantation. The increasing prevalence of cardiovascular diseases among aging populations sustains steady demand. Hospitals and specialized cardiac centers remain primary end-users, supporting high procedure volumes. Ongoing innovation and patient awareness are expected to maintain North America’s leading position in the market.

Asia-Pacific to Witness as a Fastest Growing Region

Asia Pacific is witnessing the fastest growth in the prosthetic heart valve market due to expanding healthcare access and rising cardiovascular disease incidence. Emerging economies such as China, India, and Japan are seeing increased investments in hospitals and cardiac care facilities, facilitating higher procedure volumes. Leading global and regional players, including Lepu Medical Technology, MicroPort, and Venus Medtech, are actively expanding their distribution and clinical support networks. Adoption of minimally invasive valve procedures and technological improvements in valve design are gaining traction. Government initiatives to improve healthcare infrastructure further support market expansion. The combination of demographic trends and rising awareness is driving Asia Pacific’s rapid growth in the prosthetic heart valve segment.

Market Players Outlook

The major companies operating in the global prosthetic heart valves market include Edwards Lifesciences Corp., Medtronic plc., Abbott Laboratories, Boston Scientific Corp., and LivaNova PLC, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In October 2025, Medtronic plc introduced the Avalus Ultra™ bioprosthesis valve in India. This product launch expands Medtronic’s surgical (biological/tissue valve) portfolio and enhances its offering across both surgical and transcatheter segments.

• In September 2025, Edwards Lifesciences Corporation launched a next-generation transcatheter heart valve platform in India, aimed at treating aortic stenosis through minimally invasive procedures. The launch represents a geographic expansion of its latest valve technology and strengthens its presence in emerging markets with commercially available, revenue-generating products.

• In August 2025, Medtronic plc received FDA approval for an expanded indication of its Evolut™ transcatheter aortic valve system, enabling use in redo procedures for previously implanted valves. This development broadens the clinical application of its existing valve platform and directly expands its commercial product footprint in the transcatheter segment.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global prosthetic heart valves market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.